GlycoMimetics, Inc.
11/04/2016
PDF
Add to Briefcase

GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the quarter ended September 30, 2016.

"For GlycoMimetics, the third quarter was highlighted by continued achievements in our clinical development programs, particularly with regard to GMI-1271, our clinical-stage E-selectin antagonist. We announced initiation of a Phase 1 clinical trial of GMI-1271 in multiple myeloma, expanding potential uses of the drug candidate. We continue to enroll the Phase 2 portion of the GMI-1271 AML trial in both newly diagnosed and relapsed/refractory patients. We also announced the initiation of a Phase 1 clinical trial of our next drug candidate, GMI-1359, in healthy volunteers. After the close of the quarter, we announced the acceptance of multiple abstracts for six posters and one oral presentation at ASH in December 2016. With our new trial initiations and continued enrollment in our ongoing trials, we expect to be in a position to provide additional news on the clinical development of GMI-1271 and GMI-1359 in late 2016 and throughout 2017," said Rachel King, GlycoMimetics' Chief Executive Officer.

Key Operational Highlights:

Third Quarter 2016 Financial Results:

About GMI-1271

GMI-1271 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. Preclinical research points to the drug's potential role in moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy. In preclinical studies using animal models of AML, the results of which were presented at meetings of the American Society of Hematology (ASH), GMI-1271 was also associated with a reduction of chemotherapy-induced neutropenia and chemotherapy-induced mucositis.

About GMI-1359

GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. Since E-selectin and CXCR4 are both adhesion molecules that keep cancer cells in the bone marrow, we believe that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that affect the bone marrow such as AML and MM, as compared to targeting CXCR4 alone. In December 2015 at the annual meeting of the American Society of Hematology, we presented preclinical data suggesting that GMI-1359 may enhance the ability of chemotherapy to target and improve survival rates in patients with a high-risk form of mutated AML.

About Rivipansel

GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. Using our expertise in carbohydrate chemistry and knowledge of carbohydrate biology, we are developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. We believe this represents an innovative approach to drug discovery to treat a wide range of diseases. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding the clinical development of the Company's drug candidates and the presentation of clinical data. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company's annual report on Form 10-K that was filed with the U.S. Securities and Exchange Commission (SEC) on February 29, 2016, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

               
GlycoMimetics, Inc.
Condensed Statements of Operations
(In thousands, except share and per share data)
 
 
Three months ended September 30, Nine months ended September 30,
(Unaudited) (Unaudited)
2016 2015 2016 2015
 
Revenue $ 18 $ - $ 18 $ 20,035
 
Cost and expenses:
Research and development expense 5,921 5,038 17,221 18,089
General and administrative expense   1,984     2,133     6,352     5,844  
Total costs and expenses   7,905     7,171     23,573     23,933  
 
Loss from operations (7,887 ) (7,171 ) (23,555 ) (3,898 )
 
Other income   32     3     74     10  
 
Net loss and net comprehensive loss $ (7,855 ) $ (7,168 ) $ (23,481 ) $ (3,888 )
 
 
 
Net loss per share - basic and diluted $ (0.34 ) $ (0.38 ) $ (1.14 ) $ (0.20 )
Weighted average shares - basic and diluted 23,049,347 19,025,623 20,638,129 18,999,705
 
 
 
GlycoMimetics, Inc.
Balance Sheet Data
(In thousands)
 
 
September 30, December 31,
2016 2015
(unaudited)
 
Cash and cash equivalents $ 45,283 $ 46,803
 
Working capital 41,104 39,497
 
Total assets 48,011 48,462
 
Total liabilities 6,259 7,991
 
Stockholders' equity 41,751 40,472
 

GlycoMimetics, Inc.
Investor Contact:
Shari Annes, 650-888-0902
sannes@annesassociates.com
or
Media Contact:
Jamie Lacey-Moreira, 410-299-3310
jamielacey@presscommpr.com

Source: GlycoMimetics, Inc.

News Provided by Acquire Media